CGRP Monoclonal Antibodies Are NOT Receptor Blockers
The CGRP monoclonal antibodies (eptinezumab, erenumab, fremanezumab, and galcanezumab) are NOT receptor blockers—they bind directly to the CGRP ligand itself (except erenumab, which targets the receptor). In contrast, the CGRP antagonists-gepants (atogepant, rimegepant, ubrogepant, zavegepant) ARE receptor blockers that competitively inhibit the CGRP receptor 1, 2.
Mechanism of Action Distinction
The calcitonin gene-related peptide modulators fall into two distinct mechanistic categories:
CGRP Monoclonal Antibodies (mAbs)
- Eptinezumab, fremanezumab, and galcanezumab: These bind to and neutralize the CGRP peptide ligand itself in circulation, preventing it from reaching and activating receptors 1
- Erenumab: This is the exception among mAbs—it binds to the CGRP receptor rather than the ligand, but it is still NOT classified as a "receptor blocker" in the traditional pharmacological sense; it's a receptor-targeting antibody 1
CGRP Antagonists-Gepants (Receptor Blockers)
- Atogepant and rimegepant (for prevention): These are small-molecule competitive antagonists that directly block the CGRP receptor 1
- Rimegepant, ubrogepant, and zavegepant (for acute treatment): These function as receptor blockers at the CGRP receptor complex (CLR-RAMP1) 2, 3
Clinical Implications
The distinction matters for several reasons:
- Route of administration: mAbs require subcutaneous injection or IV infusion, while gepants are oral medications—a key patient preference factor 1
- Pharmacokinetics: mAbs have much longer half-lives (weeks) compared to gepants (hours), affecting dosing frequency
- Cost: mAbs are substantially more expensive than traditional preventive medications, though gepants are also costly 1
- Selectivity: Recent data shows gepants (ubrogepant, atogepant) have some cross-reactivity with other calcitonin family receptors, particularly AMY1 receptors, though they remain most potent at CGRP receptors 3
Guideline Context
The 2025 ACP guidelines position both CGRP antagonists-gepants and CGRP-mAbs as second-line options after failure of traditional preventive medications (beta-blockers, valproate, venlafaxine, amitriptyline), with topiramate as a third-line option 1. The guidelines emphasize shared decision-making regarding mode of administration and cost when choosing between these CGRP-targeting therapies.
Common pitfall: Clinicians sometimes incorrectly assume all CGRP modulators work through receptor blockade. Understanding that most mAbs neutralize the ligand (not block the receptor) helps explain their distinct pharmacological profiles and clinical characteristics.